PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Evox Therapeutics reaches gene therapy agreement

Partnership with Icahn School of Medicine will involve developing exoAAV vectors for heart disease patients.

Evox Therapeutics, an exosome therapeutics company, has announced a collaboration agreement with the New York-based Icahn School of Medicine.

The partnership will involve developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology with a view to improving therapies for heart disease.

The organisations will also concentrate on long-term challenges in cardiovascular medicine, including the effective and safe delivery of genetic drugs to cardiomyocytes.

By enhancing the precision of gene delivery to heart muscle cells while also navigating the immune response, exoAAV technology could potentially boost the use of gene therapy in the cardiovascular disease area.

Susmita Sahoo, associate professor of medicine, cardiology at Icahn Mount Sinai, has been researching the use of exosomes in gene therapy for many years, and her group’s findings were recently published in the cardiovascular disease journal Circulation.

Indeed, the Evox and Icahn Mount Sinai collaboration further develops this foundation by combining Evox’s exosome technology with Icahn Mount Sinai’s understanding of gene delivery.

Dr Sahoo was enthusiastic about what the partnership could yield: “We are excited to work with Evox to advance this research. We hope to unlock the therapeutic potential of exosome-encapsulated AAVs, which could represent a transformative step in gene therapy and a major breakthrough in the treatment of heart diseases.”

Dr Antonin de Fougerolles, chief executive officer of Evox, explained: “This project is a significant step for Evox as it expands the reach of exosome-mediated delivery of genetic medicines to another organ outside of the liver.”

He added: “The work done by Dr Sahoo and colleagues has already demonstrated that exosomes can significantly improve the in vivo delivery of AAV gene therapy to cardiomyocytes and could do so even in the presence of high levels of neutralising anti-AAV antibodies, thus offering the possibility of an exosome-mediated gene therapy that could be used to treat all patients irrespective of their immunological status.

“We believe that we can play an important role in advancing this important research toward clinical impact.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026